ESPR received a significant boost as bempedoic acid was the only non-statin newly recommended in the 2025 ESC/EAS guidelines for lowering LDL-C and reducing cardiovascular risk, achieving Class I or IIa recommendations across multiple patient groups. This endorsement reinforc...